医学临床研究
   Apr. 5, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2023, Vol. 40 Issue (10): 1504-1507    DOI: 10.3969/j.issn.1671-7171.2023.10.018
Original Articles Current Issue | Archive | Adv Search |
Effect of Leuprorelin Acetate Combined with Dydrogesterone on Ovarian Endometriosis Patients and its Influence on Postoperative Recurrence
JIANG Li, FAN Yating, WANG Ying, et al
Department of Gynecology, Baoji High-tech Zone Hospital, Baoji Shaanxi 721300
Download: PDF (1178 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To investigate the effect of Leuprorelin acetate combined with Dydrogesterone on ovarian endometriosis patients and its influence on postoperative recurrence. 【Methods】A total of 110 patients with ovarian endometriosis admitted to Baoji High-tech Zone Hospital from August 2019 to June 2021 were selected and divided into observation group and control group according to the random number table method, with 55 cases in each group. Both groups received laparoscopic surgery. The control group received leuprorelin acetate treatment after surgery, while the observation group received dydrogesterone treatment on the basis of the control group. Both groups were treated for 3 months. The clinical efficacy, adverse reactions, postoperative recurrence, serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), visual analogue scale (VAS) scores for pelvic pain, dysmenorrhea, and dyspareunia before and after treatment were compared between the two groups. 【Results】One year after treatment, the total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the serum FSH, LH, E2 levels of both groups were lower than those before treatment (P<0.05), and the serum FSH, LH, E2 levels of the observation group were lower than those of the control group (P<0.05). After treatment, the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in both groups were lower than those before treatment (P<0.05), and the VAS scores for pelvic pain, dysmenorrhea, and dyspareunia in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). During the follow-up period of one year, one patient in the control group and two patients in the observation group were lost to follow-up, resulting in a follow-up rate of 97.27%(107/110). The postoperative recurrence rate in the observation group (3.77%) was lower than that in the control group (16.67%) (P<0.05). 【Conclusion 】 Leuprorelin acetate combined with Dydrogesterone is effective in treating ovarian endometriosis. It can improve serum hormone levels, reduce pelvic pain, dysmenorrhea, dyspareunia, and postoperative recurrence risk with good safety and reliability.
Key wordsEndometriosis      Ovary      Leuprorelin/PD      Dydrogesterone/PD     
Received: 01 August 2023     
PACS:  R711.71  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
JIANG Li
FAN Yating
WANG Ying
et al
Cite this article:   
JIANG Li,FAN Yating,WANG Ying, et al. Effect of Leuprorelin Acetate Combined with Dydrogesterone on Ovarian Endometriosis Patients and its Influence on Postoperative Recurrence[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(10): 1504-1507.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.10.018     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I10/1504
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech